Chemical Namemepolizumab
Dosage FormInjection (subcutaneous; 100 mg)
Drug ClassMonoclonal antibodies
SystemRespiratory, Cardiovascular
CompanyGlaxoSmithKline plc
Approval Year2015


  • Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nucala (mepolizumab) Prescribing Information2019GlaxoSmithKline LLC, Philadelphia, PA